PFE Pfizer Inc (NYSE) -2.41% Jan 28 2026: Feb 3 earnings may change outlook
The most important fact is simple: PFE stock closed lower on Jan 28 2026 at $25.86, down -2.42%, as investors rotated ahead of Pfizer Inc.’s Feb 3 earnings. The company reports results on 2026-02-03 (08:30 ET), and guidance, margin details, and Paxlovid sales will drive near-term moves. Trading finished with volume of 44,250,370 shares as the Healthcare sector lagged. This earnings spotlight covers valuation, technicals, analyst tone, and Meyka AI model forecasts to prepare investors for the report
PFE stock earnings preview and key catalysts
Pfizer Inc (PFE) reports earnings on Feb 3 2026 at 08:30 ET, and investors focus on margins, product mix, and COVID-19 treatment volumes. Consensus sentiment sits near neutral: 4 Buy, 9 Hold, 1 Sell. Expect statements on Comirnaty, Paxlovid, and recent pricing negotiations. A surprise on revenue or margin will move PFE stock sharply at the open.
PFE stock price action and valuation snapshot
Today PFE stock closed $25.86, off -0.64 on the session, with a day high of $26.39 and low of $25.76. Trailing EPS is 1.72 and the trailing P/E is 15.04, below many large-cap pharma peers. Market cap stands at $147.06B. The dividend per share is 1.72, giving an implied yield near 6.65%, and payout ratio sits at 0.99.
Meyka AI grade and forecast for PFE stock
Meyka AI rates PFE with a score out of 100: 70.47 (B+) — BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects monthly $24.96 and yearly $23.46, implying an implied downside of -9.28% from today’s $25.86. Forecasts are model-based projections and not guarantees.
Analyst consensus, price targets and expected ranges
Analysts show a mixed view with more Holds than Buys. Price target dispersion suggests a trading range. A reasonable view for PFE stock is a bull case near $30.00, base case near $25.00, and bear case near $20.00, driven by revenue mix and generic competition. Street consensus remains centered, not aggressive.
Technicals and liquidity for PFE stock
Short-term indicators are neutral. RSI is 54.16, MACD histogram near 0.02, and ADX 14.84, indicating no strong trend. Bollinger bands run $24.54–$26.03. Average volume is 65,633,383, while today’s volume was 44,250,370, so liquidity is ample but below average. Watch a break above $26.50 or below $25.00 for directional trade signals.
Risks, sector context, and near-term drivers
Primary risks to PFE stock include Medicare price negotiations, patent expirations, and weaker Paxlovid demand. The Healthcare sector has shown moderate volatility, and macro rates affect dividend stocks. Positive catalysts include stronger-than-expected margins or upside on key franchises. Monitor management commentary on capital allocation and guidance.
Final Thoughts
Key takeaways: PFE stock closed $25.86 on Jan 28 2026, down -2.42%, ahead of earnings on Feb 3 2026 (08:30 ET). Valuation appears reasonable with a trailing P/E of 15.04 and dividend yield near 6.65%, but payout sustainability is a focus given a payout ratio near 0.99. Meyka AI’s forecast model projects a one-year level of $23.46, implying -9.28% from today. Analysts lean neutral, with a practical price range of $20.00–$30.00. For traders, watch volume and a post-earnings reaction to margin guidance. For income investors, confirm dividend coverage after the report. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are projections and not guarantees. Sources: Reuters and MarketWatch.
FAQs
When does Pfizer report earnings and why it matters for PFE stock?
Pfizer reports earnings on Feb 3 2026 at 08:30 ET. Results matter for PFE stock because revenue mix, Paxlovid trends, and margin guidance will drive short-term price moves.
What is Meyka AI’s forecast for PFE stock?
Meyka AI’s forecast model projects a monthly price of $24.96 and a yearly price of $23.46 for PFE stock. These are model-based projections and not guarantees.
What are realistic price targets for PFE stock after earnings?
Reasonable targets post-earnings are a bull case near $30.00, base near $25.00, and bear near $20.00, depending on guidance and Paxlovid sales changes.
How does Pfizer’s dividend affect PFE stock valuation?
Pfizer pays $1.72 per share, giving PFE stock an implied yield near 6.65%. High yield supports income investors but raises questions about payout sustainability.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
